Daewoong Pharmaceutical Presents Phase 3 Clinical Trial Results of New Diabetes Treatment ‘Enavogliflozin’ and Roadmap to Enter 50 Countries by 2030
Highly anticipated to be an effective therapeutic for its excellent efficacies in reducing blood glucose levels and safety SEOUL, South Korea, Nov. 2, 2022 /PRNewswire/ -- Daewoong Pharmaceutical (Daewoong), the South Korea-based global healthcare company, announced the phase III clinical trial results of the new diabetes drug 'Enavogliflozin.' Daewoong (CEO Sengho...
Ascletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19
-- ASC11 is an in-house discovered oral small molecule drug candidate, targeting 3-chymotrypsin like protease (3CLpro) -- In antiviral cellular assays with infectious SARS-CoV-2, ASC11 demonstrated higher potency against SARS-CoV-2 than other 3CLpro inhibitors including Nirmatrelvir, S-217622, PBI-0451 and EDP-235, etc. -- Ascletis owns global intellectual property rights for ASC11 HANGZHOU and SHAOXING, China, Nov. 2, 2022 /PRNewswire/...
WAT Medical Entrusted By Geely Auto To Develop Neuromodulation Technologies To Improve Travel Experiences
VANCOUVER, BC, Nov. 2, 2022 /PRNewswire/ -- With the foreseeable increase in outdoor travelling in the near future, as well as the ever-expanding prospects of self-driving vehicles that have been reported to increase the incidence of nausea and vomiting, motion sickness is becoming a continuously growing concern for millions of people worldwide. EmeTerm is an FDA cleared device...
I Peace partners with the California Institute for Regenerative Medicine [CIRM]
PALO ALTO, Calif., Nov. 2, 2022 /PRNewswire/ -- I Peace, Inc. (https://www.ipeace.com) announced that the company has agreed to join the California Institute for Regenerative Medicine's (CIRM) Industry Resource Partner Program to pave way for the provision of Good Manufacturing Practice (GMP) iPSCs for various research programs funded by CIRM. I Peace...
OrthAlign, Inc. Adds Balance Feature to their Lantern® Platform, Including Indications for Primary and Revision Knee Arthroplasty
New feature offers soft-tissue balancing to aid in accurate component positioning ALISO VIEJO, Calif., Nov. 1, 2022 /PRNewswire/ -- With its recent addition of the Balance feature to the Lantern platform, OrthAlign, Inc. is delivering an efficient, easy-to-use, cost-effective instrument that aids surgeons in soft-tissue balancing during primary and revision knee replacement procedures. The first soft-tissue feature to appear...
Real-World Application of Lunit INSIGHT to be Spotlighted at RSNA 2022 (Oral Presentations)
7 oral presentations and 1 e-poster highlighting Lunit's most up-to-date research on its AI solution for radiology, have been accepted by RSNA Program will include studies evaluating the performance of Lunit's commercial AI software across massive real-world population groups Software now clinically used in more than 1,000 global medical sites ...
Henlius’ Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Receives NMPA Approval for the Treatment of sqNSCLC
SHANGHAI, Nov. 1, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696. HK) announced that its first self-developed innovative anti-PD-1 monoclonal antibody (mAb) HANSIZHUANG (generic name: serplulimab injection), in combination with carboplatin and albumin-bound paclitaxel for the first-line treatment of unresectable locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC), has been approved by the National Medical Products Administration (NMPA), providing...
Inteleos to Convene Global Health Leaders to Develop Community-Specific Ultrasound Programs Aimed at Lowering Maternal and Fetal Mortality Rates in Kenya
Alliance aims to reduce maternal mortality in Kenya by 10 percent in five years ROCKVILLE, Md., Nov. 1, 2022 /PRNewswire/ -- Inteleos™, and its global partners, Kenya Women and Children's Wellness Centre, The Kenya Healthcare Federation and HealthEd Global will host a Stakeholder Summit set for November 9 and 10 in Nairobi, Kenya. The Stakeholder Summit will bring together healthcare leaders from...
HAVAS HEALTH & YOU APPOINTS PAUL KINSELLA CHIEF CREATIVE OFFICER OF HH&Y EUROPE
Leadership Addition Helps Drive Creative Transformation Across the Region and Elevates Role of Creativity In Health NEW YORK, Nov. 1, 2022 /PRNewswire/ -- The European health market is expected to grow more than 15 percent by 2025, and Havas Health & You's European business has expanded to match – doubling in size since 2017...
Eyeguard System, the Privacy Filter Specialist, Launched New Wellness & Lifestyle Brand “ANBAC”
Healthy Eyes, Mind, and Body SEOUL, South Korea, Nov. 1, 2022 /PRNewswire/ -- Eyeguard System, a privacy filter manufacturer with 20 years of experience, announced that it will launch "ANBAC", new wellness & lifestyle brand for improving life starting from relived eyes. “Wellness starts within the eyes.” is the brand ANBAC’s core message. "ANBAC" is a brand...
